Logo image of ABOS

ACUMEN PHARMACEUTICALS INC (ABOS) Stock Price, Quote, News and Overview

NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD

1.46  -0.11 (-7.01%)

After market: 1.4316 -0.03 (-1.95%)

ABOS Quote, Performance and Key Statistics

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (7/28/2025, 8:05:58 PM)

After market: 1.4316 -0.03 (-1.95%)

1.46

-0.11 (-7.01%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.36
52 Week Low0.86
Market Cap88.43M
Shares60.57M
Float53.47M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-18 2025-08-18/bmo
IPO07-01 2021-07-01


ABOS short term performance overview.The bars show the price performance of ABOS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

ABOS long term performance overview.The bars show the price performance of ABOS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ABOS is 1.46 USD. In the past month the price increased by 30.36%. In the past year, price decreased by -51.17%.

ACUMEN PHARMACEUTICALS INC / ABOS Daily stock chart

ABOS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.36 333.00B
AMGN AMGEN INC 14.51 162.01B
GILD GILEAD SCIENCES INC 14.6 140.60B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.34B
REGN REGENERON PHARMACEUTICALS 12.61 60.32B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.35B
ARGX ARGENX SE - ADR 103.69 36.43B
ONC BEONE MEDICINES LTD-ADR 7.52 31.87B
BNTX BIONTECH SE-ADR N/A 27.11B
SMMT SUMMIT THERAPEUTICS INC N/A 20.39B
INSM INSMED INC N/A 19.30B
BIIB BIOGEN INC 8.17 18.94B

About ABOS

Company Profile

ABOS logo image Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

Company Info

ACUMEN PHARMACEUTICALS INC

427 Park St.

Charlottesville VIRGINIA US

CEO: Daniel O'Connell

Employees: 61

ABOS Company Website

ABOS Investor Relations

Phone: 19253688508

ACUMEN PHARMACEUTICALS INC / ABOS FAQ

What is the stock price of ACUMEN PHARMACEUTICALS INC today?

The current stock price of ABOS is 1.46 USD. The price decreased by -7.01% in the last trading session.


What is the ticker symbol for ACUMEN PHARMACEUTICALS INC stock?

The exchange symbol of ACUMEN PHARMACEUTICALS INC is ABOS and it is listed on the Nasdaq exchange.


On which exchange is ABOS stock listed?

ABOS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ACUMEN PHARMACEUTICALS INC stock?

11 analysts have analysed ABOS and the average price target is 8.93 USD. This implies a price increase of 511.3% is expected in the next year compared to the current price of 1.46. Check the ACUMEN PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ACUMEN PHARMACEUTICALS INC worth?

ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 88.43M USD. This makes ABOS a Micro Cap stock.


How many employees does ACUMEN PHARMACEUTICALS INC have?

ACUMEN PHARMACEUTICALS INC (ABOS) currently has 61 employees.


What are the support and resistance levels for ACUMEN PHARMACEUTICALS INC (ABOS) stock?

ACUMEN PHARMACEUTICALS INC (ABOS) has a support level at 1.22 and a resistance level at 1.58. Check the full technical report for a detailed analysis of ABOS support and resistance levels.


Should I buy ACUMEN PHARMACEUTICALS INC (ABOS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ACUMEN PHARMACEUTICALS INC (ABOS) stock pay dividends?

ABOS does not pay a dividend.


When does ACUMEN PHARMACEUTICALS INC (ABOS) report earnings?

ACUMEN PHARMACEUTICALS INC (ABOS) will report earnings on 2025-08-18, before the market open.


What is the Price/Earnings (PE) ratio of ACUMEN PHARMACEUTICALS INC (ABOS)?

ACUMEN PHARMACEUTICALS INC (ABOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.94).


What is the Short Interest ratio of ACUMEN PHARMACEUTICALS INC (ABOS) stock?

The outstanding short interest for ACUMEN PHARMACEUTICALS INC (ABOS) is 3.19% of its float. Check the ownership tab for more information on the ABOS short interest.


ABOS Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to ABOS. When comparing the yearly performance of all stocks, ABOS is a bad performer in the overall market: 82.64% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ABOS Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ABOS. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABOS Financial Highlights

Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS decreased by -84.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.08%
ROE -75.05%
Debt/Equity 0.19
Chartmill High Growth Momentum
EPS Q2Q%-92%
Sales Q2Q%N/A
EPS 1Y (TTM)-84.76%
Revenue 1Y (TTM)N/A

ABOS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ABOS. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners70.41%
Ins Owners6.03%
Short Float %3.19%
Short Ratio4.4
Analysts
Analysts87.27
Price Target8.93 (511.64%)
EPS Next Y-27.95%
Revenue Next YearN/A